22 results
8-K
EX-10.1
UNCY
Unicycive Therapeutics Inc
14 Mar 24
Unicycive Announces $50 Million Private Placement
4:28pm
8-K
EX-10.1
UNCY
Unicycive Therapeutics Inc
14 Mar 24
Entry into a Material Definitive Agreement
4:00pm
8-K
EX-10.1
UNCY
Unicycive Therapeutics Inc
10 Apr 23
Entry into a Material Definitive Agreement
6:16am
8-K
EX-10.2
UNCY
Unicycive Therapeutics Inc
6 Mar 23
Unicycive Announces up to $130 Million Financing to Commercialize and Launch Investigational New Drug Renazorb
5:02pm
8-K
EX-10.1
UNCY
Unicycive Therapeutics Inc
6 Mar 23
Unicycive Announces up to $130 Million Financing to Commercialize and Launch Investigational New Drug Renazorb
5:02pm
8-K
EX-10.1
oljjojngtseo94b3 iqu
2 Feb 23
Unicycive Announces Exclusive License and Development Agreement with Lotus for Renazorb in the Republic of Korea
4:45pm
8-K
EX-10.1
arbwk
18 Jul 22
Expands and accelerates Renazorb opportunity in important markets for patients with hyperphosphatemia through local partner with deep domain expertise
4:15pm
S-1/A
EX-10.2
v9msoyz vfv8
7 Jun 21
IPO registration (amended)
7:01am
S-1/A
EX-10.6
6kfk 9m6epwex2bjco
7 Jun 21
IPO registration (amended)
7:01am
S-1/A
EX-10.4
92lkq5 zbi8
7 Jun 21
IPO registration (amended)
7:01am
S-1/A
EX-10.1
ggl892
7 Jun 21
IPO registration (amended)
7:01am
S-1/A
EX-10.5
906yx
7 Jun 21
IPO registration (amended)
7:01am
S-1
EX-10.8
lrfbxwlqywr
21 May 21
IPO registration
4:07pm
S-1
EX-10.9
j6hg5u0
21 May 21
IPO registration
4:07pm
S-1
EX-10.10
3ipa93 0zb32u
21 May 21
IPO registration
4:07pm
S-1
EX-10.3
z18325
21 May 21
IPO registration
4:07pm
S-1
EX-10.7
gcve8sq2tpprlz4f89v
21 May 21
IPO registration
4:07pm
DRS/A
EX-10.1
gg9qjy 2ad753w8
29 Apr 21
Draft registration statement (amended)
12:00am
DRS/A
EX-10.4
g3qlwa 7cz8shb
29 Apr 21
Draft registration statement (amended)
12:00am
DRS/A
EX-10.5
8b5zstipknberbw5vb7
29 Apr 21
Draft registration statement (amended)
12:00am